The iNTS-GMMA vaccine: a promising step in non-typhoidal Salmonella vaccine development

Click to increase image sizeClick to decrease image size

Declarations of interest

R Canals is employed by the GSK group of companies, holds GSK shares, and is the Project Leader at GSK Vaccines Institute for Global Health Srl for developing the iNTS-GMMA vaccine funded by a EU Horizon 2020 and an EDCTP grants. GSK Vaccines Institute for Global Health Srl is an affiliate of GlaxoSmithKline Biologicals SA. MN Ramasamy is Chief Investigator on a Phase 1 trial of the iNTS-GMMA vaccine sponsored by the University of Oxford and funded by a EU Horizon 2020 grant. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contribution statement

All authors have (1) substantially contributed to the conception and design of the review article and interpreting the relevant literature, and (2) been involved in writing the review article or revised it for intellectual content.

Additional information

Funding

This manuscript was not funded. The iNTS-GMMA vaccine program has received funding from the EU Horizon 2020 research and innovation programme under the project Vacc-iNTS (grant agreement number 815439), and from the EDCTP2 programme supported by the European Union under the project PEDVAC-iNTS (RIA2019AMR-2658).